Completed
PHASE3
INTERVENTIONAL
NCT05024032
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Mean Percent Change From Baseline in Body Weight
TimeFrame:
Baseline, Week 52
Description:
Mean Percent Change from Baseline in Body Weight. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + Sex + Presence of Comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Measure:
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
TimeFrame:
Week 52
Description:
Percentage of Participants who Achieve ≥5% Body Weight Reduction. A logistic regression model was used for this analysis.
Trial Information
NCT ID
NCT05024032
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025